MYC and the control of apoptosis

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 7, 2014, Pages

  McMahon, Steven B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER PATIENT; CELL DEATH; HUMAN; NONHUMAN; ONCOGENE MYC; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; NEOPLASMS; PHYSIOLOGY;

MAMMALIA;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; GENES, MYC; HUMANS; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923815801     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014407     Document Type: Article

References (61)

1. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
2. Amanullah A, Liebermann DA, Hoffman B. 2000. p53- independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation. Oncogene 19: 2967-2977.
3. Arhel NJ, Packham G, Townsend PA, Collard TJ, AM HZ, Sharp A, Cutress RI, Malik K, Hague A, Paraskeva C, et al. 2003. The retinoblastoma protein interacts with Bag-1 in human colonic adenoma and carcinoma derived cell lines. Int J Cancer 106: 364-371.
4. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. 1991. Constitutive c-myc expression in an IL-3-dependent my-eloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915-1922.
5. Berger R, Flexor M, Le Coniat M, Larsen CJ. 1996. Pres- ence of three recurrent chromosomal reaarrangements, t(2;3) (p12;q37), del(8)(q24), and t(14;18), in an acute lymphoblastic leukemia. Cancer Genet Cytogenet 86: 76-79.
6. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. 1993. Point mutations in the c-Myc transactivation domain are common in Burkitt’s lymphoma and mouse plasmacytomas. Nat Genet 5: 56-61.
7. Boone DN, Qi Y, Li Z, Hann SR. 2011. Egr1 mediates p53- independent c-Myc-induced apoptosis via a noncanon-ical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci 108: 632-637.
8. Cato AC, Mink S. 2001. BAG-1 family of cochaperones in the modulation of nuclear receptor action. J Steroid Bio-chem Mol Biol 78: 379-388.
9. Chang DW, Claassen GF, Hann SR, Cole MD. 2000. The c-Myc transactivation domain is a direct modulator ofapoptotic versus proliferative signals. Mol Cell Biol 20: 4309-4319.
10. Claveria C, Giovinazzo G, Sierra R, Torres M. 2013. Myc- driven endogenous cell competition in the early mam-malian embryo. Nature 500: 39-44.
11. de la Cova C, Abril M, Bellosta P, Gallant P, Johnston LA. 2004. Drosophila myc regulates organ size by inducing cell competition. Cell 117: 107-116.
12. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
13. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe Cite this article as Cold Spring. Harb Perspect Med 2014;4:a0144077.
14. SW. 1998. E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev 12: 2434-2442.
15. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. 1999. Disruption of the ARF-Mdm2-p53 tumor suppres- sor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669.
16. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
17. Gabay M, Li Y, Felsher DW. 2014. MYC activation is a hall- mark of cancer initiation and maintenance. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014407.
18. Gotz R, Kramer BW, Camarero G, Rapp UR. 2004. BAG-1 haplo-insufficiency impairs lung tumorigenesis. BMC Cancer 4: 85.
19. Hagiyama H, Adachi T, Yoshida T, Nomura T, Miyasaka N, Honjo T, Tsubata T. 1999. Signaling through the antigen receptor of B lymphocytes activates a p53-independ- ent pathway of c-Myc-induced apoptosis. Oncogene 18: 4091-4098.
20. Haupt Y, Rowan S, Shaulian E, Kazaz A, Vousden K, Oren M. 1997. p53 mediated apoptosis in HeLa cells: Transcrip-tion dependent and independent mechanisms. Leukemia 11: 337-339.
21. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. 2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807-811.
22. Huang M, Weiss WA. 2013. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3: a014415.
23. Jacobsen KA, Prasad VS, Sidman CL, Osmond DG. 1994. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of Em-myc transgenic mice. Blood 84: 2784-2794.
24. Johnston LA. 2014. Socializing with MYC: Cell competition in development and as a model for premalignant cancer. Cold Spring Harb Perspect Med doi: 10.1101/cshper-spect.a014274.
25. Johnston JM, Yu MT, Carroll WL. 1991. c-myc hypermuta-tion is ongoing in endemic, but not all Burkitt’s lympho-ma. Blood 78: 2419-2425.
26. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. 1997. Tumor suppres-sion at the mouse INK4a locus mediated by the alterna- tive reading frame product p19ARF. Cell 91: 649-659.
27. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci 95: 8292-8297.
28. Knezevich S, Ludkovski O, Salski C, Lestou V, Chhanabhai M, Lam W, Klasa R, Connors JM, Dyer MJ, Gascoyne RD, et al. 2005. Concurrent translocation of BCL-2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia 19: 659-663.
29. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. 2004. Anti- apoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6: 241-249.
30. Levens D. 2013. Cellular MYCro economics: Balancing MYC function with MYC expression. Cold Spring Harb Perspect Med 3: a014233.
31. Levine AJ, Oren M. 2009. The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 9: 749-758.
32. Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR. 2001. BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: A unique role for proHB-EGF in cell survival reg-ulation. J Biol Chem 276: 30127-30132.
33. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
34. Lowe SW, Cepero E, Evan G. 2004. Intrinsic tumour sup-pression. Nature 432: 307-315.
35. Luders J, Demand J, Papp O, Hohfeld J. 2000. Distinct iso- forms of the cofactor BAG-1 differentially affect Hsc70 chaperone function. J Biol Chem 275: 14817-14823.
36. Martin-Subero JI, Odero MD, Hernandez R, Cigudosa JC, Agirre X, Saez B, Sanz-Garcia E, Ardanaz MT, Novo FJ, Gascoyne RD, et al. 2005. Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL-2-positive ger- minal center B-cell lymphomas. Genes Chromosomes Cancer 43: 414-423.
37. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubrama- nian S, Mele DA, Bergeron L, Sims RJ III. 2011. Targeting MYC dependence in cancer by inhibiting BET bromodo- mains. Proc Natl Acad Sci 108: 16669-16674.
38. Mukhopadhyay S, Readling J, Cotter PD, Shrimpton AE, Sidhu JS. 2005. Transformation of follicular lymphoma to Burkitt-like lymphoma within a single lymph node. Human Pathology 36: 571-575.
39. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. 2008. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell 14: 447-457.
40. Neiman PE, Thomas SJ, Loring G. 1991. Induction of apo- ptosis during normal and neoplastic B-cell development in the bursa of Fabricius. Proc Natl Acad Sci 88: 5857-5861.
41. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
42. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM. 2012. BET bro-modomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120: 2843-2852.
43. Ozdek A, Sarac S, Akyol MU, Sungur A, Yilmaz T. 2004. c-myc and bcl-2 expression in supraglottic squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg 131: 77-83.
44. Rahl PB, Young RA. 2014. MYC and transcription elonga- tion. Cold Spring Harb Perspect Med 4: a020990.
45. Roussel MF, Robinson GW. 2013. Role of MYC in medullo-blastoma. Cold Spring Harb Perspect Med 3: 014308.
46. Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC. 1995. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-indepen- dent mechanisms. Oncogene 11: 2411-2418.
47. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. 2014. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 4: 0142828.
48. Sears R, Leone G, DeGregori J, Nevins JR. 1999. Ras enhanc- es Myc protein stability. Mol Cell 3: 169-179.
49. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR. 1992. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257: 212-214.
50. Strasser A, Harris AW, Bath ML, Cory S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by coop-eration between myc and bcl-2. Nature 348: 331-333.
51. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC. 1995. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activ- ity. Cell 80: 279-284.
52. Topham CH, Taylor SS. 2013. Mitosis and apoptosis: How is the balance set? Curr Opin Cell Biol 25: 780-785.
53. Trudel M, Lanoix J, Barisoni L, Blouin MJ, Desforges M, L’Italien C, D’Agati V. 1997. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. J Exp Med 186: 1873-1884.
54. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. 2008. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
55. Vassilev LT. 2004. Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeu- tics. Cell Cycle 3: 419-421.
56. Vita M, Henriksson M. 2006. The Myc oncoprotein as a therapeutic target for human cancer. Seminar Cancer Biol 16: 318-330.
57. Wang HG, Takayama S, Rapp UR, Reed JC. 1996. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci 93: 7063-7068.
58. Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, Span-didos DA. 1987. Rodent fibroblast tumours expressing human myc and ras genes: Growth, metastasis and en- dogenous oncogene expression. Br J Cancer 56: 251-259.
59. Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M. 1993. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt’s lymphoma. Oncogene 8: 2741-2748.
60. Zhang XY, Pfeiffer HK, Mellert HS, Stanek TJ, Sussman RT, Kumari A, Yu D, Rigoutsos I, Thomas-Tikho-nenko A, Seidel HE, et al. 2011. Inhibition of the single downstream target BAG-1 activates the latent apoptotic potential of MYC. Mol Cell Biol 31: 5037-5045.
61. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apo- ptosis and immortalization. Genes Dev 12: 2424-2433.